The global genitourinary drugs market size was estimated at USD 29.0 billion in 2022 and is projected to reach USD 31.75 billion by 2030, growing at a CAGR of 1.1% from 2023 to 2030. The growth of this market is largely driven by the rising prevalence of genitourinary disorders, which continues to create significant demand for effective treatments.

According to the World Health Organization (WHO), as of March 2022, approximately 491 million individuals worldwide between the ages of 15 and 49—representing 13% of the global population—are infected with herpes simplex virus (HSV)-2 each year. Similarly, data from the Centers for Disease Control and Prevention (CDC) indicates that in 2021, there were 572,000 new cases of genital herpes infections in the United States, with women being more likely than men to contract HSV-2. The high prevalence of these conditions is expected to continue driving market growth over the forecast period.

In addition to the existing patient base, the increasing number of pipeline drugs is anticipated to expand market opportunities. For example, in July 2021, AiCuris Anti-infective Cures AG initiated a phase 3 clinical trial of pritelivir for treating immunocompromised patients with HSV, reflecting ongoing collaborative research initiatives among major pharmaceutical companies seeking to strengthen their leadership in the branded genitourinary drugs segment.

Furthermore, in June 2023, Novartis announced an agreement to acquire Chinook Therapeutics, a clinical-stage biopharmaceutical company. This acquisition aligns with Novartis’s strategic objective to expand its renal portfolio and introduce new medicines in the genitourinary space, highlighting the industry’s focus on innovation and portfolio diversification.

Key Market Trends & Insights:

• In 2022, North America dominated the global genitourinary drugs market, accounting for a revenue share of 37.0%. The region’s leadership can be attributed to its well-established healthcare infrastructure, high awareness of genitourinary disorders, and strong presence of major pharmaceutical companies investing in research and development.

• Meanwhile, the Asia Pacific region is expected to emerge as the fastest-growing market, projected to achieve a compound annual growth rate (CAGR) of 4.8% over the forecast period. Growth in this region is driven by rising healthcare expenditure, increasing access to advanced treatments, and growing awareness of genitourinary diseases among the population.

• When analyzed by indication, the prostate cancer segment held the largest revenue share, representing 28.3% of the market in 2022. The prominence of this segment is due to the high prevalence of prostate cancer worldwide and the demand for effective therapeutic options.

• In terms of product type, the hormonal therapy segment accounted for a significant share of the market in 2022. Hormonal therapies are widely used in treating various genitourinary conditions, particularly prostate cancer, as they help in regulating hormone levels and controlling disease progression, making them a key contributor to market revenue.

Order a free sample PDF of the Genitourinary Drugs Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 29.0 Billion

• 2030 Projected Market Size: USD 31.75 Billion

• CAGR (2023-2030): 1.1%

• North America: Largest market in 2022

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Key players in the genitourinary drugs market are actively focusing on growth-oriented strategies, which include mergers and acquisitions, continuous development of existing devices, hosting promotional events, and driving technological advancements. These initiatives are aimed at strengthening their competitive position, expanding product portfolios, and addressing the rising demand for effective treatments.

For instance, in April 2023, GSK plc announced positive outcomes from its EAGLE-2 and EAGLE-3 clinical trials for gepotidacin. The Phase III trial results were highly encouraging, highlighting the potential of gepotidacin to become the first-in-class orally administered antibiotic designed for the treatment of uncomplicated urinary tract infections (uUTIs) in female adolescents and adults. This development underscores the company’s commitment to introducing innovative therapies that address unmet medical needs.

Similarly, in March 2023, Pfizer Inc. entered into a definitive merger agreement with Seagen Inc., a biotechnology firm recognized for its expertise in discovering, developing, and commercializing cancer medicines. Seagen is also regarded as a pioneer in antibody-drug conjugate (ADC) technology, which is transforming the field of targeted cancer therapy. Through this collaboration, Pfizer and Seagen aim to accelerate the development of next-generation cancer treatments, leveraging Pfizer’s scale and global capabilities alongside Seagen’s advanced ADC technology, ultimately providing innovative therapeutic solutions for patients worldwide.

Key Players

• Abbott

• Bristol-Myers Squibb Co.

• Novartis AG

• Genentech, Inc.

• F. Hoffmann-La RocheLtd.

• Ionis Pharmaceuticals, Inc.

• Eli Lilly and Company

• Merck & Co., Inc.

• Pfizer, Inc.

• AstraZeneca

• GlaxoSmithKline

• Teva Pharmaceutical Industries Ltd.

• Bayer AG

• Allergan

• Antares Pharma

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The genitourinary drugs market is characterized by modest growth, driven primarily by the increasing incidence of genitourinary disorders and a growing pipeline of novel therapies. While established regions with strong healthcare infrastructure continue to dominate the market, emerging economies are seen as offering promising growth opportunities due to improving access, rising awareness, and expansion of research & development activity. Key challenges such as patent expirations, the influx of generics and counterfeit products, and competitive pressure are likely to temper growth.